Raed A Dweik

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4514179/publications.pdf

Version: 2024-02-01

74 papers

5,019 citations

28 h-index 70 g-index

74 all docs

74 docs citations

times ranked

74

6924 citing authors

#	Article	IF	CITATIONS
1	An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F <scp>e</scp> _{NO}) for Clinical Applications. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 602-615.	5.6	2,047
2	Detection of Lung Cancer by Sensor Array Analyses of Exhaled Breath. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1286-1291.	5.6	514
3	Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1342-1347.	7.1	342
4	Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, at-Risk Phenotype among Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1033-1041.	5.6	252
5	The Breathprints in Patients With Liver Disease Identify Novel Breath Biomarkers in Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2014, 12, 516-523.	4.4	94
6	Cardiovascular Biomarkers in Exhaled Breath. Progress in Cardiovascular Diseases, 2012, 55, 34-43.	3.1	91
7	Exhaled breath analysis: the new frontier in medical testing. Journal of Breath Research, 2008, 2, 030301.	3.0	83
8	Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. European Journal of Gastroenterology and Hepatology, 2014, 26, 82-87.	1.6	82
9	Isoprene in the Exhaled Breath is a Novel Biomarker for Advanced Fibrosis in Patients with Chronic Liver Disease: A Pilot Study. Clinical and Translational Gastroenterology, 2015, 6, e112.	2.5	79
10	Strategic Plan for Lung Vascular Research. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1554-1562.	5.6	73
11	Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 877-886.	6.1	71
12	An Official American Thoracic Society Statement: Pulmonary Hypertension Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 345-355.	5.6	70
13	Single Exhaled Breath Metabolomic Analysis Identifies Unique Breathprint in Patients With Acute Decompensated Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1463-1464.	2.8	68
14	The Rise and Fall of Hyaluronan in Respiratory Diseases. International Journal of Cell Biology, 2015, 2015, 1-15.	2.5	62
15	Determinants of Exhaled Breath Condensate pH in a Large Population With Asthma. Chest, 2011, 139, 328-336.	0.8	61
16	Clinical Characterization and Survival of Patients with Borderline Elevation in Pulmonary Artery Pressure. Pulmonary Circulation, 2013, 3, 916-925.	1.7	49
17	<i>O -Linked \hat{I}^2- <i>N -Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2015, 131, 1260-1268.</i></i>	1.6	48
18	Primary pulmonary hypertension: an overview of epidemiology and pathogenesis Cleveland Clinic Journal of Medicine, 2003, 70, S2-S2.	1.3	46

#	Article	IF	Citations
19	Outcomes of \hat{I}^2 -blocker use in pulmonary arterial hypertension: a propensity-matched analysis. European Respiratory Journal, 2015, 46, 750-760.	6.7	43
20	Breath Analysis in Pulmonary Arterial Hypertension. Chest, 2014, 145, 551-558.	0.8	39
21	Hypertensive Urgency Induced by an Interaction of Mirtazapine and Clonidine. Pharmacotherapy, 2000, 20, 476-478.	2.6	38
22	Shot-noise Limited Faraday Rotation Spectroscopy for Detection of Nitric Oxide Isotopes in Breath, Urine and Blood. Scientific Reports, 2015, 5, 9096.	3.3	38
23	Modification of Hyaluronan by Heavy Chains of Inter-α-Inhibitor in Idiopathic Pulmonary Arterial Hypertension. Journal of Biological Chemistry, 2014, 289, 6791-6798.	3.4	36
24	Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 190-199.	3.2	36
25	Pulmonary hypertension and the search for the selective pulmonary vasodilator. Lancet, The, 2002, 360, 886-887.	13.7	32
26	Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors. Hepatology Communications, 2020, 4, 1041-1055.	4.3	32
27	Informing Healthcare Decisions with Observational Research Assessing Causal Effect. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 14-23.	5.6	32
28	Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respiratory Medicine, 2016, 117, 65-72.	2.9	30
29	High Levels of Exhaled Nitric Oxide (NO) and NO Synthase III Expression in Lesional Smooth Muscle in Lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 414-418.	2.9	28
30	Analysis of breath volatile organic compounds in children with chronic liver disease compared to healthy controls. Journal of Breath Research, 2015, 9, 026002.	3.0	28
31	Prognostic Value of Echocardiographic Changes in Patients with Pulmonary Arterial Hypertension Receiving Parenteral Prostacyclin Therapy. Journal of the American Society of Echocardiography, 2014, 27, 733-741.e2.	2.8	27
32	Serum Chloride Levels Track With SurvivalÂin Patients With Pulmonary ArterialÂHypertension. Chest, 2018, 154, 541-549.	0.8	24
33	Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension. PLoS ONE, 2016, 11, e0156042.	2.5	23
34	Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 564-575.	2.9	22
35	A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications. Clinical and Translational Gastroenterology, 2016, 7, e201.	2.5	21
36	Specific O-GlcNAc modification at Ser-615 modulates eNOS function. Redox Biology, 2020, 36, 101625.	9.0	21

#	Article	IF	CITATIONS
37	Heart Rate Recovery is an Important Predictor of Outcomes in Patients with Connective Tissue Diseaseâ€"Associated Pulmonary Hypertension. Pulmonary Circulation, 2015, 5, 565-576.	1.7	20
38	Changes in main pulmonary artery diameter during followâ€up have prognostic implications in pulmonary arterial hypertension. Respirology, 2017, 22, 1649-1655.	2.3	19
39	O-GlcNAc Transferase Regulates Angiogenesis in Idiopathic Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2019, 20, 6299.	4.1	19
40	The scientific rationale for the use of simple masks or improvised facial coverings to trap exhaled aerosols and possibly reduce the breathborne spread of COVID-19. Journal of Breath Research, 2020, 14, 030201.	3.0	18
41	Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0191869.	2.5	17
42	Isolation and analysis of sugar nucleotides using solid phase extraction and fluorophore assisted carbohydrate electrophoresis. MethodsX, 2016, 3, 251-260.	1.6	16
43	Assessing the kinetics of microbubble appearance in cirrhotic patients using transthoracic saline contrastâ€enhanced echocardiography. Echocardiography, 2017, 34, 1439-1446.	0.9	14
44	Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0197700.	2.5	14
45	What is the best approach to a high systolic pulmonary artery pressure on echocardiography?. Cleveland Clinic Journal of Medicine, 2016, 83, 256-260.	1.3	14
46	Leptin deficiency recapitulates the histological features of pulmonary arterial hypertension in mice. International Journal of Clinical and Experimental Pathology, 2014, 7, 1935-46.	0.5	13
47	Molecular breath analysis identifies the breathprint of renal failure. Journal of Breath Research, 2017, 11, 026009.	3.0	12
48	Bariatric surgery in patients with pulmonary hypertension. Surgery for Obesity and Related Diseases, 2018, 14, 1581-1586.	1.2	12
49	Treprostinil Iontophoresis in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1014-1016.	5.6	11
50	Novel Methods in Pulmonary Hypertension Phenotyping in the Age of Precision Medicine (2015 Grover) Tj ETQq	0 0 0 rgBT	/Overlock 10
51	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. Chest, 2020, 158, 2546-2555.	0.8	11
52	Platelet glycolytic metabolism correlates with hemodynamic severity in pulmonary arterial hypertension. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L562-L569.	2.9	11
53	Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls. Physiological Reports, 2014, 2, e12038.	1.7	10
54	Evaluation of left ventricular diastolic function profile in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. Clinical Cardiology, 2017, 40, 356-363.	1.8	9

#	Article	IF	CITATIONS
55	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2732-2737.	5.2	9
56	Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Patients With Obesity. Chest, 2022, 162, 684-692.	0.8	9
57	Portable Breath Monitoring: A New Frontier in Personalized Health Care. Electrochemical Society Interface, 2016, 25, 63-67.	0.4	8
58	Is Pulmonary Hypertension a Metabolic Disease?. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 973-975.	5.6	7
59	Gasometric gradients between blood obtained from the pulmonary artery wedge and pulmonary artery positions in pulmonary arterial hypertension. Respiratory Research, 2019, 20, 6.	3.6	6
60	Abnormal levels of apolipoprotein Aâ€I in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-7.	1.7	6
61	Pulmonary Hypertension and Precision Medicine through the "Omics―Looking Glass. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1558-1560.	5.6	5
62	A pilot study on the kinetics of metabolites and microvascular cutaneous effects of nitric oxide inhalation in healthy volunteers. PLoS ONE, 2019, 14, e0221777.	2.5	5
63	Comparison of volatile organic compound profiles in exhaled breath versus plasma headspace in different diseases. Journal of Breath Research, 2020, 14, 036003.	3.0	5
64	Do single or sequential measurements of leptin and adiponectin in plasma have prognostic value in pulmonary arterial hypertension?. Pulmonary Circulation, 2017, 7, 727-729.	1.7	4
65	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. Journal of Heart and Lung Transplantation, 2021, 40, 614-622.	0.6	4
66	Surge capacity and capability of intensive care units across a large healthcare system: An operational blueprint for regional integration. American Journal of Disaster Medicine, 2021, 16, 179-192.	0.3	4
67	Update on Pulmonary Vascular Diseases 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 26-31.	5.6	3
68	Why patients who die of worsening pulmonary arterial hypertension are not on parenteral prostacyclin analog treatment?. Journal of Heart and Lung Transplantation, 2014, 33, 221.	0.6	3
69	Response. Chest, 2013, 143, 273-274.	0.8	2
70	Elevated pulmonary pressure: A novel risk marker in kidney disease?. Kidney International, 2015, 88, 7-9.	5.2	2
71	Pediatric Pulmonary Hypertension. Annals of the American Thoracic Society, 2016, 13, 967-969.	3.2	2
72	The breath print represents a novel biomarker of malnutrition in pulmonary arterial hypertension: a proofâ€ofâ€concept study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1645-1652.	2.6	2

#	Article	IF	CITATIONS
73	Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension. Chest, 2017, 151, 1189-1192.	0.8	O
74	Cutaneous Iontophoresis of Vasoactive Medications in Patients with Scleroderma―Associated Pulmonary Arterial Hypertension. Microcirculation, 2021, , e12734.	1.8	0